Omalizumab is only used for the long-term treatment of patients with IgE-mediated asthma, which generally shows effectiveness after at least 12 to 16 weeks of treatment with the product.
Omalizumab binds to IgE, thereby preventing IgE from binding to basophils and mast cells, and is used clinically in the treatment of persons with asthma mediated by IgE. This product needs to be administered for a long period of time, with at least 12 to 16 weeks of treatment required to show efficacy. After 16 weeks of treatment with this product, its therapeutic effectiveness should be evaluated to determine whether to continue treatment with this product.
Common adverse reactions to this product include headache, fever, epigastric pain, pain and redness at the injection site, etc. It is contraindicated for those who are allergic to any of the components in this product.
This product needs to be used by a physician, the efficacy of this product can not be observed in the short term, please adhere to the long-term use of the drug.